ReviewArthritis & rheumatology (Hoboken, N.J.)2021
Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
Review in Arthritis & rheumatology (Hoboken, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.Immunotherapy · 2025Pooled it
- Article
- Durable Response to Durvalumab in Occult Small-Cell Lung Cancer With Immune Checkpoint Inhibitor-Related Inflammatory Arthritis With Polymyalgia Rheumatica-Like Features.Geriatrics & gerontology international · 2026Article
- Article
- Immune checkpoint inhibitor-related arthritis and oral disorders: shared pathophysiology and clinical implications for rheumatology and oral health.Cancer cell international · 2025Review
- Malignancy in Idiopathic Inflammatory Myopathies: Recent Insights.Clinical reviews in allergy & immunology · 2025Review
- Article
- Immune checkpoint-induced arthritis: a comprehensive single-cohort descriptive analysis from clinical evaluation to histology.Frontiers in medicine · 2025Article
- Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action.Brain sciences · 2024Review
- The Current and Future of Biomarkers of Immune Related Adverse Events.Rheumatic diseases clinics of North America · 2024Review
- Article
- Predictive value and accuracy of [European journal of nuclear medicine and molecular imaging · 2023Article
- Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.The oncologist · 2023Article
- Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update.International journal of molecular sciences · 2023Review
- Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study.Frontiers in pharmacology · 2023Article
- Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.Frontiers in immunology · 2022Review
- Article
- Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR.Journal for immunotherapy of cancer · 2021Review
- Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study.Journal for immunotherapy of cancer · 2021Observational
- Updates in toxicities associated with immune checkpoint inhibitors.Expert review of clinical immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Rheumatologists increasingly receive consults for patients treated with immune checkpoint inhibitors (ICIs) for cancer. ICIs can cause inflammatory syndromes known as immune-related adverse events (IRAEs). Several rheumatic IRAEs have been reported, including inflammatory arthritis, polymyalgia rheumatica, and myositis. For patients who present with musculoskeletal symptoms while receiving ICI therapy, it is important to have an algorithm for evaluation. The differential diagnosis includes a range of musculoskeletal syndromes, such as crystalline arthritis, mechanical issues, and osteoarthritis, in addition to IRAEs. After diagnosing a rheumatic IRAE, rheumatologists must work with the patient and the oncologist to form a treatment plan. Treatment of IRAEs is guided by severity. Evidence for management is limited to observational studies. Inflammatory arthritis and polymyalgia rheumatica are treated with nonsteroidal antiinflammatory drugs in mild cases, glucocorticoids for moderate-to-severe cases, and sometimes require other disease-modifying antirheumatic drugs. Myositis due to ICIs can be accompanied by myocarditis or myasthenia gravis. Glucocorticoids and withholding the ICI are usually required to treat myositis; some patients with severe myositis require intravenous immunoglobulin or plasmapheresis. Further research is needed to optimize treatment of IRAEs that does not compromise the antitumor effect of ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.